[go: up one dir, main page]

MX2013010997A - Ensayo para clasificacion de compuestos que disminuyen selectivamente el numero de celulas madre de cance. - Google Patents

Ensayo para clasificacion de compuestos que disminuyen selectivamente el numero de celulas madre de cance.

Info

Publication number
MX2013010997A
MX2013010997A MX2013010997A MX2013010997A MX2013010997A MX 2013010997 A MX2013010997 A MX 2013010997A MX 2013010997 A MX2013010997 A MX 2013010997A MX 2013010997 A MX2013010997 A MX 2013010997A MX 2013010997 A MX2013010997 A MX 2013010997A
Authority
MX
Mexico
Prior art keywords
csc
classification
cance
mothers
compounds
Prior art date
Application number
MX2013010997A
Other languages
English (en)
Other versions
MX345893B (es
Inventor
Barry Smith
Carlos Cordon-Cardo
Daniel Petrylak
Josep Domenech
Mireia Castilla Martin
Original Assignee
Rogosin Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rogosin Inst filed Critical Rogosin Inst
Publication of MX2013010997A publication Critical patent/MX2013010997A/es
Publication of MX345893B publication Critical patent/MX345893B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G01N33/575—
    • G01N33/57555—
    • G01N33/5759—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invención proporciona, entre otras cosas, un método para identificar un agente que disminuye selectivamente el número de células madre de cáncer (CSCs). Este método incluye (a) contactar una CSC de una población de células con un agente candidato; y (b) determinar si el agente candidato reduce la supervivencia o crecimiento de la CSC o incrementa la diferenciación de la CSC en una forma relativa a una CSC que no ha sido contactada con el agente candidato. El método se puede utilizar como una clasificación de alto rendimiento.
MX2013010997A 2011-03-24 2012-03-22 Ensayo para clasificación de compuestos que disminuyen selectivamente el número de células madre de cáncer. MX345893B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161467265P 2011-03-24 2011-03-24
PCT/US2012/030103 WO2012129393A1 (en) 2011-03-24 2012-03-22 Assay for screening compounds that selectively decrease the number of cancer stem cells

Publications (2)

Publication Number Publication Date
MX2013010997A true MX2013010997A (es) 2014-06-23
MX345893B MX345893B (es) 2017-02-22

Family

ID=46879743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010997A MX345893B (es) 2011-03-24 2012-03-22 Ensayo para clasificación de compuestos que disminuyen selectivamente el número de células madre de cáncer.

Country Status (17)

Country Link
US (2) US20140364402A1 (es)
EP (1) EP2689249B1 (es)
JP (1) JP6002748B2 (es)
KR (1) KR101945065B1 (es)
CN (1) CN103688175B (es)
AU (1) AU2012230850B2 (es)
BR (1) BR112013024476B1 (es)
CA (1) CA2830613A1 (es)
DK (1) DK2689249T3 (es)
ES (1) ES2586599T3 (es)
HU (1) HUE030159T2 (es)
IL (1) IL228171A (es)
MX (1) MX345893B (es)
PL (1) PL2689249T3 (es)
PT (1) PT2689249T (es)
RU (1) RU2013146849A (es)
WO (1) WO2012129393A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6187980B2 (ja) * 2014-12-03 2017-08-30 国立大学法人 大分大学 Ｄｎａ傷害型物質のスクリーニング方法
RU2702910C2 (ru) * 2018-12-20 2019-10-14 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ снижения количества стволовых клеток рака молочной железы
KR102353109B1 (ko) * 2020-02-24 2022-01-19 부산대학교 산학협력단 상피성장인자-유사도메인 8 또는 이의 활성화제를 유효성분으로 함유하는 암줄기세포 마커 발현 암질환 예방 또는 치료용 약학조성물
CN111363821A (zh) * 2020-03-19 2020-07-03 宁波晶点医药研究开发有限公司 Ifi16作为抗肿瘤耐药增效及逆转的药物靶点的应用
CN112843238B (zh) * 2021-02-26 2023-03-10 中国科学技术大学 包含微管蛋白抑制剂和Notch抑制剂的药物组合物及其应用
CN116609525B (zh) * 2023-05-26 2023-10-27 杭州圣域生物医药科技有限公司 基于细胞内aldh3b1蛋白水平以筛选染色质重塑复合体抑制剂的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512256A (pt) * 2004-06-17 2008-02-19 Massachusetts Inst Technology método para caracterizar o estágio de desenvolvimento ou patologia de uma amostra de tecido; método de identificação de uma célula de interesse ou de sincìcios multe-nuclear de interesse; método para diagnóstico de pré-neoplasia ou neoplasia; métodos de identificação de um ou mais agentes anti-tumorìgenos e método de preparação de uma amostra de tecido de mamìfero adequada para a identificação de células
US10538742B2 (en) 2004-11-12 2020-01-21 Cambridge Enterprise Limited Methods and means related to cancer stem cells
GB0515305D0 (en) * 2005-07-26 2005-08-31 Procure Therapeutics Ltd Stem cell markers 1
WO2008030616A2 (en) * 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Monitoring cancer stem cells
KR101523698B1 (ko) * 2007-01-22 2015-05-29 마크로제닉스 웨스트 인코퍼레이티드 사람 암 줄기세포
US20110191868A1 (en) * 2008-04-10 2011-08-04 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
US20110020221A1 (en) * 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
WO2011038300A1 (en) * 2009-09-24 2011-03-31 The Trustees Of Columbia University In The City Of New York Cancer stem cells, kits, and methods

Also Published As

Publication number Publication date
PT2689249T (pt) 2016-09-20
NZ615669A (en) 2015-08-28
BR112013024476B1 (pt) 2022-06-14
EP2689249A4 (en) 2014-12-31
HK1191693A1 (zh) 2014-08-01
ES2586599T3 (es) 2016-10-17
KR101945065B1 (ko) 2019-02-01
US20160187320A1 (en) 2016-06-30
EP2689249B1 (en) 2016-05-25
US20140364402A1 (en) 2014-12-11
PL2689249T3 (pl) 2017-09-29
HUE030159T2 (en) 2017-05-29
IL228171A (en) 2017-09-28
MX345893B (es) 2017-02-22
KR20140016348A (ko) 2014-02-07
AU2012230850B2 (en) 2015-08-27
CN103688175A (zh) 2014-03-26
BR112013024476A2 (pt) 2017-02-14
JP6002748B2 (ja) 2016-10-05
CN103688175B (zh) 2015-09-09
JP2014509867A (ja) 2014-04-24
CA2830613A1 (en) 2012-09-27
EP2689249A1 (en) 2014-01-29
WO2012129393A1 (en) 2012-09-27
AU2012230850A1 (en) 2013-04-18
RU2013146849A (ru) 2015-04-27
DK2689249T3 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
ES2507520T3 (es) Aislamiento y/o identificación de células madre con potencial de diferenciación adipocitario, condrocitario y pancreático
BR112016024072A2 (pt) métodos, kits e aparelho para ampliar uma população de células
MX2013010997A (es) Ensayo para clasificacion de compuestos que disminuyen selectivamente el numero de celulas madre de cance.
MX2021005777A (es) Suministro selectivo de material a celulas.
ECSP13012597A (es) Agentes de unión a CD33
GT201300276A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
MX2019011040A (es) Composiciones y metodos para potenciar la expresion genica.
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
MX2016016076A (es) Composiciones de celulas t mejoradas.
TR201904270T4 (tr) Tanımlı koşullar altında insan pluripotent kök hücrelerinin hematoendotelyal farklılaşması için yöntemler ve materyaller.
MX2016008251A (es) Medios para cultivo celular.
MX380555B (es) Combinación de anticuerpos anti-gen 3 de la activación de linfocito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
MX2016004575A (es) Metodos de modificacion de celulas huespedes.
IN2014CN03084A (es)
ES2479542T1 (es) Métodos y composiciones para su uso en terapias celulares
MX350533B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
MX2016008232A (es) Procedimientos para obtener aceite microbiano a partir de células microbianas.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
BR112017018885A2 (pt) método de cultura celular para células-tronco mesenquimais
HK1218310A1 (zh) 鉴定细胞群体、特别是间充质干细胞群体的多色流式细胞术方法
CL2015003599A1 (es) Solucion que contiene theralosa y dextrano para transplantar celulas de mamiferos
IN2015DN00143A (es)
CR20120254A (es) Células madre multipotenciales en el árbol de billary extrahepática y métodos de aislamiento del mismo
AR085409A1 (es) Firmas microbianas como indicadores de exposicon a radiacion
AR094389A1 (es) USO DE INHIBIDORES DE iNOS PARA AUMENTAR EL RENDIMIENTO VÍRICO EN CULTIVOS

Legal Events

Date Code Title Description
FG Grant or registration